Terms: = Prostate cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
64 results:
1. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
2. ezh2 as a potential therapeutic target for gastrointestinal cancers.
Hashemi M; Nazdari N; Gholamiyan G; Paskeh MDA; Jafari AM; Nemati F; Khodaei E; Abyari G; Behdadfar N; Raei B; Raesi R; Nabavi N; Hu P; Rashidi M; Taheriazam A; Entezari M
Pathol Res Pract; 2024 Jan; 253():154988. PubMed ID: 38118215
[TBL] [Abstract] [Full Text] [Related]
3.
Boldrini L; Bardi M
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628609
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer.
Clermont PL
Epigenomics; 2023 Jan; 15(2):75-87. PubMed ID: 36974615
[TBL] [Abstract] [Full Text] [Related]
5. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing.
Fong KW; Zhao JC; Lu X; Kim J; Piunti A; Shilatifard A; Yu J
Mol Cell; 2022 Dec; 82(24):4611-4626.e7. PubMed ID: 36476474
[TBL] [Abstract] [Full Text] [Related]
6. ezh2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in prostate cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
[TBL] [Abstract] [Full Text] [Related]
7. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/ezh2/ androgen receptor signaling pathway.
Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
[TBL] [Abstract] [Full Text] [Related]
8. LINC00963: A potential cancer diagnostic and therapeutic target.
Xie Z; Zhong C; Shen J; Jia Y; Duan S
Biomed Pharmacother; 2022 Jun; 150():113019. PubMed ID: 35462329
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of GATA2 in prostate cancer by a clinically available small molecule.
Kaochar S; Rusin A; Foley C; Rajapakshe K; Robertson M; Skapura D; Mason C; Berman De Ruiz K; Tyryshkin AM; Deng J; Shin JN; Fiskus W; Dong J; Huang S; Navone NM; Davis CM; Ehli EA; Coarfa C; Mitsiades N
Endocr Relat Cancer; 2021 Nov; 29(1):15-31. PubMed ID: 34636746
[TBL] [Abstract] [Full Text] [Related]
10. The Role of Tumor-related LncRNA PART1 in cancer.
Chen J; Meng E; Lin Y; Shen Y; Hu C; Zhou G; Yuan C
Curr Pharm Des; 2021; 27(40):4152-4159. PubMed ID: 34225608
[TBL] [Abstract] [Full Text] [Related]
11. Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer.
Liu RJ; Li SY; Liu LQ; Xu B; Chen M
Bioengineered; 2021 Dec; 12(1):2377-2388. PubMed ID: 34077304
[TBL] [Abstract] [Full Text] [Related]
12. Clinical and Biological Features of Neuroendocrine prostate cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract] [Full Text] [Related]
13. Inhibition of ezh2 Enhances the Antitumor Efficacy of Metformin in prostate cancer.
Kong Y; Zhang Y; Mao F; Zhang Z; Li Z; Wang R; Liu J; Liu X
Mol Cancer Ther; 2020 Dec; 19(12):2490-2501. PubMed ID: 33024029
[TBL] [Abstract] [Full Text] [Related]
14. HNF1B, ezh2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.
Dundr P; Bártů M; Hojný J; Michálková R; Hájková N; Stružinská I; Krkavcová E; Hadravský L; Kleissnerová L; Kopejsková J; Hiep BQ; Němejcová K; Jakša R; Čapoun O; Řezáč J; Jirsová K; Franková V
Sci Rep; 2020 Sep; 10(1):14365. PubMed ID: 32873863
[TBL] [Abstract] [Full Text] [Related]
15. FOXM1-Dependent Transcriptional Regulation of ezh2 Induces Proliferation and Progression in prostate cancer.
Tian JH; Mu LJ; Wang MY; Zeng J; Long QZ; Bin-Guan ; Wang W; Jiang YM; Bai XJ; Du YF
Anticancer Agents Med Chem; 2021; 21(14):1835-1841. PubMed ID: 32735528
[TBL] [Abstract] [Full Text] [Related]
16. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating ezh2.
Pan MZ; Song YL; Gao F
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
[TBL] [Abstract] [Full Text] [Related]
17. MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in prostate cancer.
Aghdam AM; Amiri A; Salarinia R; Masoudifar A; Ghasemi F; Mirzaei H
Crit Rev Eukaryot Gene Expr; 2019; 29(2):127-139. PubMed ID: 31679268
[TBL] [Abstract] [Full Text] [Related]
18. HNF1B-mediated repression of SLUG is suppressed by ezh2 in aggressive prostate cancer.
Wang J; He C; Gao P; Wang S; Lv R; Zhou H; Zhou Q; Zhang K; Sun J; Fan C; Ding G; Lan F
Oncogene; 2020 Feb; 39(6):1335-1346. PubMed ID: 31636385
[TBL] [Abstract] [Full Text] [Related]
19. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract] [Full Text] [Related]
20. ezh2 promotes gastric cancer cells proliferation by repressing p21 expression.
Xu J; Wang Z; Lu W; Jiang H; Lu J; Qiu J; Ye G
Pathol Res Pract; 2019 Jun; 215(6):152374. PubMed ID: 30952377
[TBL] [Abstract] [Full Text] [Related]
[Next]
